Bone density and bone turnover markers in patients with epilepsy on chronic antiepileptic drug therapy

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 3, 2007, Pages 466-471

  Kulak, Carolina Aguiar Moreira ^a   Borba, Victória Z C ^a   Silvado, Carlos Eduardo ^a   De Paola, Luciano ^a   Seibel, Markus J ^b   Bilezikian, John P ^c   Boguszewski, César L ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Columbia University ^*  (United States)

Author keywords

Antiepileptic drugs; Bone turnover markers; Phenobarbital

Indexed keywords

EID: 34250167230     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302007000300016     Document Type: Article

References (26)

1. Engel JJ. Epileptic syndromes. In: Seizures and Epilepsy. Philadelphia: Davis Company, 1989. pp. 195-201.
2. a ed. São Paulo: Lemos, 2000. pp. 1-10.
3. Mulder JE, Kulak CAM, Shane E. Secondary osteoporosis. In: Seibel MJ, Robins SP, Bilezikian JP (eds). Dynamics of Bone and Cartilage Metabolism. San Diego: Academic Press, 1999. pp. 527-45.
4. Kulak CAM, Borba VZC, Bilezikian JP, Silvado CE, Paola L, Boguszewski CL. Bone mineral density and serum levels of 25OHvitamin D in chronic users of antiepileptic drugs. Arq Neuropsiquiatr 2004;62(4)940-8.
5. Baer TM, Kozlowski BW, Blyler EM, Trahms CM, Taylor ML, Hogan MP. Vitamin D, calcium and bone status in children with developmental delay in relation to anticonvulsant use and ambulatory satus. Am J Clin Nutr 1997;65:1042-51.
6. Hahn TJ, Hendin BA, Scharp CB, Boisseai VC, Haddad JG. Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsivant therapy. N Engl J Med 1975;292:550-4.
7. Andress DL, Ozuna J, Tirschwell D, Grande L, Meshell J, Jacobson AF, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002;59(5):781-6.
8. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58:1348-53.
9. Pack AM, Olarte LS, Morrel MM, Flasher E, Stanley RR, Shane E. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 2003;4:169-74.
10. Pack AM. The association between antiepileptic drugs and bone disease. Epilepsy Curr 2003;3(3):91-5.
11. Hahn TJ, Bridge SJ, Scarp CR, Avioli LV. Phenobarbital-induced alterations in vitamin D metabolism. J Clin Invest 1972;51:741-8.
12. Sheth RD, Wesolowski CA, Jacob JC. Effects of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-62.
13. Sarto Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001;57:445-9.
14. Valimaki MJ, Tikhonen M, Laitinen K. Bone mineral density measured by dual-energy absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Min Res 1994;9:631-7.
15. Pack AM, Morrell MJ, Marcus R, Holloway L, Flaster E, Done S, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005;57:252-7.
16. Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002;43(12):1488-92.
17. Van Daele PL, Seibel MJ, Burger H, Hofman A, Grobbee DE, van Leeuwen JP, et al. Case control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam study. Br Med J 1996;312:482-3.
18. Gomez B, Jr, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, et al. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995;41(11):1560-6.
19. Bonde M, Garnero P, Fledelius C, Qvist P, Delmas PD, Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide type I collagen. J Bone Miner Res 1997;12(7):1028-34.
20. Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critic review. Epilepsy 2004;45(9):1141-9.
21. Foss MC, Meneghelli UG, Tabosa Verissimo JM. The effect of the anticonvulsants phenobarbital and diphenylhydantoin on intestinal absorption of calcium. Acta Physiol Lat Am 1979;29(4-5):223-8.
22. Jekins MV, Harris M, Willis MR. The effect of phenytoin on parathyroid extract and 25-hydroxycholecolecalciferol induced bone resorption: Adenosine 3′ 5′-cyclic monophosphatase production. Calcified Tissue Res 1974;16:163-7.
23. Hahn TJ, Scharp CR, Richardson CA, Halstead LR, Kahn AJ, Teitelbaum ST. Intercation of dyphenylhydantoin and phenobarbital with hormonal mediation of fetal rat bone resorption in vivo. J Clin Invest 1978;62:406-14.
24. Mokesilde L, Melsen F. Dynamic differences in trabecular bone remodeling between patients after jejuno ileal by pass for obesity and epileptic patients receiving anticonvulsant therapy. Metab Bone Dis 1980;2:77-82.
25. Weinstein RS, Bryce GF, Sappington LJ, King DW, Gallagher BB. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 1984;58:1003-9.
26. Bramswig S, Zittermann A, Berthold HK. Carbamazepine does not alter biochemical parameters of bone turnover in healthy male adults. Calcif Tissue Int 2003;73(4):356-60.